Concurrent cisplatin-based chemoradiation for cervical carcinoma: tumor response, toxicity, and serum cytokine profiles.
OBJECTIVE
To evaluate the relation between tumor response, treatment toxicity, and serum cytokine profiles in patients with cervical cancer receiving cisplatin-based chemoradiation.


METHODS
Forty-two patients with cervical carcinoma receiving chemoradiation were recruited. Hemogram, biochemistry profile, cytokine levels, tumor size, and toxicity were assessed weekly.


RESULTS
The absolute neutrophil count decreased accompanied by an increase in serum levels of G-CSF during chemoradiation. The sudden elevation of serum TGF-beta 1 and VEGF levels after the first fraction of brachytherapy accompanied with the development of greater radiation therapy (RT) morbidity. Lower pretreatment TGF-beta 1 and VEGF levels are associated with tumor response to chemoradiation.


CONCLUSIONS
The serial changes in serum cytokines during chemoradiation may correlate with tumor regression and treatment morbidity.
Yang
Yuh-Cheng
YC
Department of Gynecology and Obstetrics, Mackay Memorial Hospital, Taipei, Taiwan.
Wang
Kung-Liahng
KL
Su
Tsung-Hsien
TH
Liao
Hui-Fen
HF
Wu
Meng-Hao
MH
Chen
Tze-Chien
TC
Huang
Ming-Chao
MC
Chen
Yu-Jen
YJ
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood; D002294:Carcinoma, Squamous Cell / Q000097:blood / Q000628:therapy*; D002945:Cisplatin / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D016207:Cytokines / Q000097:blood*; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000097:blood; D006801:Humans; D015850:Interleukin-6 / Q000097:blood; D008875:Middle Aged; D009504:Neutrophils / Q000187:drug effects / Q000528:radiation effects; D011878:Radiotherapy; D016212:Transforming Growth Factor beta / Q000097:blood; D053773:Transforming Growth Factor beta1; D002583:Uterine Cervical Neoplasms / Q000097:blood / Q000628:therapy*; D042461:Vascular Endothelial Growth Factor A / Q000097:blood
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D016207:Cytokines; D015850:Interleukin-6; C508960:TGFB1 protein, human; D016212:Transforming Growth Factor beta; D053773:Transforming Growth Factor beta1; D042461:Vascular Endothelial Growth Factor A; D016179:Granulocyte Colony-Stimulating Factor; D002945:Cisplatin